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Evidence for Intramolecular Cross-Linked
A𝛼𝛼 · 𝛾𝛾 Chain Heterodimers in Plasma
Fibrinogen†
Kevin R. Siebenlist

Department of Basic Health Sciences, School of Dentistry, Marquette University, Milwaukee, WI

Michael W. Mosesson

University of Wisconsin Medical School, Sinai Samaritan Medical Center, Milwaukee, Wisconsin

Abstract
A peptide band of ∼105 kDa migrating near the 𝛾𝛾 dimer position of disulfide bond reduced human
plasma fibrinogen prepared from fresh single donor or outdated plasma was identified by SDS−PAGE.
The band, amounting to ∼2% of the total A𝛼𝛼/𝛾𝛾 chain population, was thrombin and plasmin sensitive
and reacted with antibodies to Aα or 𝛾𝛾 chains but not with antibodies to B𝛽𝛽 chains, plasminogen, or
factor XIII. Amino acid sequencing revealed a double sequence corresponding to that of A𝛼𝛼 and 𝛾𝛾
chains, indicating that the band consists of covalently cross-linked A𝛼𝛼 · 𝛾𝛾 chain heterodimers. A𝛼𝛼 · 𝛾𝛾

heterodimers were identified as a component of monomeric fibrinogen by two-dimensional SDS−PAGE
and by SDS−PAGE analysis of the monomer fraction isolated by gel sieving chromatography, thus
indicating that A𝛼𝛼 · 𝛾𝛾 heterodimers arise by intramolecular A𝛼𝛼/𝛾𝛾 chain cross-linking.
In the presence of factor XIIIa, fibrin assembly is accompanied by intermolecular covalent cross-linking,
in which ε-amino (𝛾𝛾 -glutamyl) lysine isopeptide bonds are introduced between appropriately positioned
donor lysine and acceptor glutamine residues (Pisano et al., 1968; Matačic̀ & Loewy, 1968). Cross-linking
occurs initially between 𝛾𝛾 chains to form 𝛾𝛾 dimers. Concomitantly, albeit at a slower rate, cross-linking
occurs among α chains (McKee et al., 1970; Folk & Finlayson, 1977) and to a minor extent between α
and 𝛾𝛾 chains (Mosesson et al., 1989; Amrani & Mosesson, 1989; Shainoff et al., 1991; Grøn et al., 1993).
Continued factor XIIIa activity among the existing 𝛾𝛾 dimer population results in slow progressive
evolution of 𝛾𝛾 chain multimers (Mosesson et al., 1989; Shainoff et al., 1991; Siebenlist & Mosesson,
1992). XIIIa can also cross-link fibrinogen (Kanaide & Shainoff, 1975; Mosesson et al., 1996), which forms
a translucent, nonsynergizing gel, concomitant with 𝛾𝛾 dimer formation. 𝛾𝛾 chain multimers and crosslinked α−γ hybrid chains have also been detected in XIIIa cross-linked fibrinogen polymers (Murthy &
Lorand, 1990; Shainoff et al., 1991).
Fibrinogen and fibrin can also be cross-linked by tissue transglutaminase, which follows a different
course than that of XIIIa (Chung, 1972; Purves et al., 1987; Murthy & Lorand, 1990; Shainoff et al., 1991).
α chains become cross-linked more rapidly than 𝛾𝛾 chains, and both α and 𝛾𝛾 chains become incorporated
into high molecular weight polymeric structures. There is no direct evidence that 𝛾𝛾 dimers, per se, are
formed (Purves et al., 1987; Shainoff et al., 1991), since 𝛾𝛾 chains become preferentially incorporated
into α-γ hybrids early in the cross-linking reaction (Murthy & Lorand, 1990; Shainoff et al., 1991).

Recent studies have shown that erythrocyte transglutaminase can cross-link fibrinogen (Murthy et al.,
1991), although this type of cross-linking reaction is not known to occur in vivo in circulating fibrinogen
molecules. In this report, we demonstrate the existence of a subpopulation of native fibrinogen
molecules containing intramolecular cross-links between A𝛼𝛼 and 𝛾𝛾 chains, probably mediated in vivo by
a tissue transglutaminase.

Methods
All chemicals and reagents were the highest grade available from commercial sources. Human
fibrinogen (greater than 98% coagulable) was isolated from pooled citrated plasma by glycine
precipitation (Kazal et al., 1963) and subfractionated to fraction I-2 by an established procedure
(Mosesson & Sherry, 1966). Fibrinogen concentrations were determined spectrophotometrically at 280
nm using an absorbance coefficient 𝐴𝐴1%
cm of 15.1 (Mosesson & Finlayson, 1963). Peak 1 (𝛾𝛾A, 𝛾𝛾A) and
peak 2 (𝛾𝛾A, 𝛾𝛾‘) fibrinogen were prepared from fraction I-2 by chromatography on DE-52 (Whatman Inc.,
Clifton, NJ) (Finlayson & Mosesson, 1963; Mosesson et al., 1972). Single donor plasma was obtained by
contrifugation of blood collected into acid−citrate−dextrose (9:1) supplemented with a variety of
protease/transglutaminase inhibitors [PMSF (0.5 mM, final); aprotinin (15 KIU/mL, final) (Trasylol,
Mobay Chemical Corp., New York); PPACK (2.5 μM, final) (Calbiochem, San Diego, CA); N-ethylmaleimide
(10 mM, final); EDTA (5 mM, final)]. These inhibitors were added to all solutions employed during
fibrinogen isolation. Fibrinogen was labeled with 125I using the iodine monochloride method (McFarlane,
1963), resulting in a labeling ratio of 0.6 atom of 125I per fibrinogen molecule.

Factor XIII was purified from pooled human plasma (Lorand & Gotoh, 1970); its specific activity ranged
from 2000 to 2500 Loewy units/mg (Loewy et al., 1961). Factor XIII was activated to factor XIIIa by
addition of human 𝛼𝛼-thrombin (10 units/mL) (Enzyme Research Inc., South Bend, IN) (Kanaide &
Shainoff, 1975). Plasminogen was isolated from human plasma by affinity chromatography on
lysine−Sepharose (Robbins & Summaria, 1976), activated to plasmin by incubation with streptokinase
(1:800 molar ratio) for 20 h at room temperature (Robbins & Summaria, 1970), and assayed
colorometrically using Kabi S-2251 (Chromogenix, Mölndal, Sweden).
For analysis of thrombin or plasmin susceptibility, fibrinogen (1 mg/mL) in 50 mM Tris and 100 mM NaCl,
pH 7.4, was clotted by the addition of thrombin (0.5 unit/mL) and incubated at room temperature for 1
h or digested with plasmin (0.1 unit/mL) for up to 360 min at room temperature. Digestions were
terminated by adding Laemmli sample buffer containing reducing agents.
SDS−PAGE was performed as described by Weber and Osborn (1969) for tube gels (3 mm diameter) or
on 1.5 mm slab gels using the method of Laemmli (1970). Five percent polyacrylamide gels were used
for reduced samples and 7.5% or 9% gels for disulfide bond reduced samples. Fibrinogen fractions from
a gel sieving column were analyzed on 8−25% gels using the Phast Gel System (Pharmacia, Piscataway,
NJ) and stained with 0.5% Coomassie Brilliant Blue R250 (Sigma Chemical Co., St. Louis, MO).
Immunoblotting was carried out on samples that had been separated by SDS−PAGE (Laemmli, 1970),
electroblotted onto nitrocellulose paper, and probed with polyclonal rabbit antibodies raised against the
A𝛼𝛼, B𝛽𝛽, and 𝛾𝛾 chain of fibrinogen, factor XIII, or plasminogen (Dako Corp., Carpinteria, CA) followed
by 125I-labeled goat anti-rabbit IgG.
Size exclusion chromatography on 50−100 mg fibrinogen samples was performed on a tandem pair of
1.5 × 90 cm columns that had been equilibrated in either 50 mM Tris, 100 mM NaCl, 0.5 mM PMSF, and
5 KIU/mL aprotinin, pH 7.4, buffer or the same buffer containing 500 mM NaCl and developed at a flow
rate of 15 mL/h.

For amino acid sequencing, reduced fibrinogen chains were separated on 7.5% polyacrylamide gels
(Laemmli, 1970), the regions of interest were excised from the gel, and the protein was recovered by
electroelution. The pooled and concentrated samples were reelectrophoresed, electroblotted onto a
poly(vinylidene difluoride) membrane (Matsudaira, 1987), excised, and then subjected to automated
sequencing on a model 477A Applied Biosystems pulsed liquid-phase sequencer with a model 120A online phenylthiohydantoin amino acid analyzer.

Results
Identification of a 105 kDa Peptide in Fibrinogen.
During studies originally designed to explore the cross-linking reaction between fibrin(ogen) and factor
XIIIa, a radioactive band was noted on autoradiographs of reduced un-cross-linked 125I-labeled
fibrinogen (Figure 1, lane A). This band migrated close to the 𝛾𝛾 dimer position corresponding to a
molecular mass of ∼105 kDa. This unanticipated band could also be detected on Coomassie Blue stained
SDS−PAGE gels of reduced fibrinogen (Figure 1, lane B). However, unlike 𝛾𝛾 dimers, the 105 kDa band was
thrombin sensitive, as assessed by the faster migration rate in fibrin samples compared with fibrinogen
(Figure 2). The band was also plasmin sensitive, disappearing from its SDS−PAGE position in the same
time frame as monomeric fibrinogen chains (Figure 3). On the basis of densitometric analysis of

Coomassie blue stained gels, this band represented approximately 2% of the total A𝛼𝛼 and 𝛾𝛾 chain
monomer population.

Figure 1 SDS−PAGE of fibrinogen demonstrating the presence of the 105 kDa band in fibrinogen. Lane A
is an autoradiograph of reduced un-cross-linked 125I-labeled fibrinogen separated on 9% polyacrylamide
gels. Lane B contains the same amount of fibrinogen separated under similar conditions and stained
with Coomassie Blue R250. The differences in mobility are due to slight differences in the time of
electrophoresis. The positions of the relevant fibrinogen chains and factor XIII are indicated. The
location of the 105 kDa band is designated by A𝛼𝛼 · 𝛾𝛾.

Figure 2 Thrombin sensitivity of the 105 kDa band. Aliquots of fibrinogen before and after thrombin
treatment (0.5 unit/mL for 1 h at room temperature) were separated on 7.5% polyacrylamide gels and
stained with Coomassie Blue R250. Lanes 1, cross-linked peak 2 fibrin; 2 and 4, fibrinogen; 3 and 5,

fibrin; 6, factor XIII. The positions of the relevant fibrinogen chains and factor XIII are indicated. The
location of the 105 kDa band in fibrinogen is designated by A𝛼𝛼 · 𝛾𝛾 and as 𝛼𝛼 · 𝛾𝛾 in fibrin.
The peptide chain composition of the 105 kDa band in fibrinogen (peak 2) was explored by Western
blotting of reduced fibrinogen samples. The band reacted against antibodies to A𝛼𝛼 or 𝛾𝛾 chains (Figure 4)
but did not react with antibodies against B𝛽𝛽 chains, factor XIII, or plasminogen. The A𝛼𝛼 · 𝛾𝛾 identity of
the 105 kDa band was confirmed by amino acid sequence analysis of material electroeluted from
SDS−PAGE gels. Multiple amino acids were found at each step (Table 1). The most prominent amino
acids corresponded to the 𝛾𝛾 chain sequence, whereas the others indicated the presence of A𝛼𝛼 or α
chain sequences (Table 1). About 60% of the non- 𝛾𝛾 chain amino acids were derived from the intact A𝛼𝛼
chain (Ala1-Asp2...), and approximately 15% came from a minor A𝛼𝛼 chain population lacking the Nterminal Ala residue (Asp2-Ser3...). The remaining amino acids corresponded to the fibrin α chain (Gly17Pro18...). The total recovery of A(α) chain amino acids approximated the amount recovered from the 𝛾𝛾
chains. These findings further suggested that a small proportion of the A𝛼𝛼 · 𝛾𝛾 chains had been converted
to fibrin α·γ.

Figure 3 Plasmin sensitivity of the 105 kDa band. Aliquots of fibrinogen were treated with plasmin (0.1
unit/mL) for up to 360 min at room temperature, electrophoresed on a 9% polyacrylamide gel under
reducing conditions, and stained with Coomassie Blue R250. The positions of the relevant fibrinogen
chains and factor XIII are indicated. The location of the 105 kDa band is designated by A𝛼𝛼 · 𝛾𝛾.

Figure 4 Western blots of fibrinogen. Aliquots of fibrinogen were separated on gels under reducing
conditions, electroblotted onto nitrocellulose paper, and probed with rabbit antibodies raised against
human fibrinogen A𝛼𝛼, B𝛽𝛽, or γ chains, human factor XIII, or human plasminogen followed by 125I-labeled
goat anti- A𝛼𝛼; 3, anti- B𝛽𝛽; 4, anti- 𝛾𝛾; 5, anti-factor XIII; 6, anti-plasminogen. The positions of the relevant
fibrinogen chains and factor XIII are indicated. The location of the 105 kDa band is designated by A𝛼𝛼 · 𝛾𝛾.

Table 1: Amino Acid Sequence Analysis of the 105 kDa Banda
step
chain
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Predicted Sequence
A𝛼𝛼 b Ala Asp Ser Gly Glu Gly
Asp Phe Leu Ala Glu Gly
Gly Gly
𝛼𝛼
Gly Pro
Arg Val Val
Glu
Arg
His
Gln Ser Ala
Cys
Lys
Asp
𝛾𝛾
Tyr Val
Ala
Thr Arg Asp Asn Cys
Cys Ile
Leu Asp Glu Arg
Amino Acids Found/Yield (pmol)
A𝛼𝛼 b Ala Asp Ser Gly Glu Gly
Asp Phe Leu Ala Glu Gly
Gly Gly
12
21
21
20
8
25
26
10
10
15
11
12
12
10
𝛼𝛼
Gly Pro Arg Val Val
Glu
Arg His
Gln Ser Ala
X
Lys Asp
12
7
3
9
5
8
4
8
5
8
8
6
9
𝛾𝛾
Tyr Val
Ala Thr Arg Asp Asn X
X
Ile
Leu Asp Glu Arg
31
34
27
29
16
28
29
20
19
21
17
17
a
The 105 kDa band was separated from other fibrinogen bands by SDS−PAGE under reducing conditions.
Appropriate regions of the gel were excised and protein was collected by electroelution. Concentrated
samples were rerun on SDS−PAGE, transferred to poly(vinylidene difluoride) membrane, and sequenced
on a model 477A Applied Biosystems pulsed liquid-phase sequencer. The amino acid recovery
(picomoles) at each cycle is indicated below the residue.b A minor A𝛼𝛼 chain variant (≈15%) beginning at
position 2 (Asp) was present in the samples. The sequence data for this variant was included with the
intact A𝛼𝛼 chain by putting it in register beginning at position 2.

Intramolecular Nature of the A𝛼𝛼 · 𝛾𝛾 Band.

In nonreduced fibrinogen fraction I-2 preparations, monomeric fibrinogen and the factor XIII A and B
subunits were detected, but a band migrating in the 105 kDa position was absent (Figure 5, horizontal
tube gel). When a gel of unreduced fibrinogen was run in a second dimension under reducing
conditions, the 105 kDa A𝛼𝛼 · 𝛾𝛾 band appeared in the region corresponding to fibrinogen monomer,
indicating that it was covalently incorporated into a monomeric form of fibrinogen (Figure 5, slab gel).

Figure 5 Two-dimensional SDS−PAGE of fibrinogen. In the first dimension fibrinogen was separated on a
5% gel under nonreducing conditions (horizontal tube gel). For the second dimension, the tube bel was
placed on top of a 9% gel and electrophoresed under reducing conditions. Protein bands were visualized
by staining with Coomassie Blue R250. The positions of the relevant fibrinogen chains, factor XIII, and
the A𝛼𝛼 · 𝛾𝛾 band are indicated.
We attempted to separate the 105 kDa band from the fraction I-2 fibrinogen by size exclusion
chromatography in 50 mM Tris and 0.1 or 0.5 M NaCl, pH 7.4, buffers on the premise that the fibrinogen
preparations might contain small amounts of multimeric cross-linked fibrinogen or fibrin molecules.
Under either buffer condition, fibrinogen was separated into two fractions: a minor early eluting peak
and a major peak of fibrinogen monomer (Figure 6). SDS−PAGE of peak fractions (Figure 6, inset)
revealed that the early eluting peak contained multimeric cross-linked fibrinogen or fibrin formed
through 𝛾𝛾 chain cross-linking. The fibrinogen monomer peak expressed the 105 kDa A𝛼𝛼 · 𝛾𝛾 band.

Figure 6 Size exclusion chromatography of fibrinogen. Fibrinogen was loaded onto a pair of columns
containing Sepharose 4B-CL equilibrated in 50 mM Tris, 100 mM NaCl, 0.5 mM PMSF, 5 KIU/mL Trasylol,
pH 7.4. A fast eluting minor peak and a slower eluting major peak were resolved. The inset to this figure
is an 8−25% Coomassie Blue stained Phast gel of selected fractions. Lanes: 1, starting fibrinogen; 2−7,
column fractions as indicated by arrows; 8, factor XIIIa cross-linked fibrin. The positions of the relevant
fibrinogen chains, factor XIII, and the A𝛼𝛼 · 𝛾𝛾 band are indicated.

The method of plasma collection from which the fibrinogen was isolated had little, if any, effect on the
occurrence of the A𝛼𝛼 · 𝛾𝛾 band. Plasma from fresh single donor blood that had been collected into
acid−citrate−dextrose supplemented with PMSF, aprotinin, PPACK, N-ethylmaleimide, and EDTA was
subfractionated from buffers containing these inhibitors in all solutions. SDS−PAGE analysis
demonstrated the presence of the A𝛼𝛼 · 𝛾𝛾 band (Figure 7, lane 1) in about the same amounts as had been
found in fibrinogen isolated from outdated plasma (cf. Figure 1). When a fibrinogen sample prepared
from fresh single donor plasma was chromoatographically subfractionated into peaks 1 and 2, the A𝛼𝛼 · 𝛾𝛾
band was found in both peak fractions, with a somewhat higher proportion in the peak 2 fibrinogen
(Figure 7, lanes 2 and 3).

Figure 7 Identification of the A𝛼𝛼 · 𝛾𝛾 band in fibrinogen isolated from fresh plasma. Single donor plasma
was collected into acid−citrate−dextrose (9:1) supplemented with a variety of
protease/transglutaminase inhibitors (see Methods). These same inhibitors were present in all solutions
employed during fibrinogen isolation. An aliquot of fraction I-2 fibrinogen (lane 1) was separated into
peak 1 (lane 2) and peak 2 (lane 3) fibrinogen by chromatography on DE-52. The positions on this
Coomassie Blue stained gel of the relevant fibrinogen chains, factor XIII, and the A𝛼𝛼 · 𝛾𝛾 band are
indicated.

Discussion
A band corresponding to the A𝛼𝛼 · 𝛾𝛾 chain fibrinogen band has been observed previously by other
investigations but was not recognized to consist of cross-linked A𝛼𝛼 · 𝛾𝛾 chain heterodimers. Grøn et al.
(1993) noted that the 105 kDa band reacted with antibodies directed against A𝛼𝛼 or 𝛾𝛾 chains, but they
did not analyze the band in further detail and believed that it consisted of 𝛾𝛾 dimers superimposed upon
partially degraded cross-linked A𝛼𝛼 chains. Our present experiments show that intramolecular crosslinked A𝛼𝛼 and 𝛾𝛾 chains are present in circulating monomeric fibrinogen molecules. The A𝛼𝛼 · 𝛾𝛾
heterodimers are present in a small proportion of circulating fibrinogen molecules amounting to
approximately 2% of the A𝛼𝛼/𝛾𝛾 chain population.

The A𝛼𝛼 · 𝛾𝛾 heterodimers are presumably formed by the action of a transglutaminase. Murthy et al.
(1991) recently found that transglutaminase from erythrocytes catalyzed the formation of
intermolecularly cross-linked fibrinogen polymers in vitro, suggesting to us that a tissue-type
transglutaminase is responsible for formation of these complexes in circulating fibrinogen in vivo.
However, a possible role for factor XIIIa cannot be completely discounted, since both forms of factor XIII
have been shown to produce cross-linked A𝛼𝛼 · 𝛾𝛾 chains in fibrin and fibrinogen (Mosesson et al., 1989;
Amrani & Mosesson, 1989; Shainoff et al., 1991; Grøn et al., 1993). Similarly, the region(s) of the A𝛼𝛼

chain that become(s) cross-linked to the 𝛾𝛾 chain is (are) unknown as is the chain which contributes the
lysine donor and glutamine acceptor groups.

Several plausible scenarios can be suggested to explain how A𝛼𝛼 · 𝛾𝛾 complexes form in vivo. Fibrinogen
has been shown to bind covalently to hepatocytes and endothelial cells in a calcium-dependent manner
(Barsigian et al., 1987, 1988; Greenberg et al., 1987; Martinez et al., 1989; Barsigian & Martinez, 1990).
Tissue transglutaminase evidently is the processing enzyme mediating the binding because there was
preferential cross-linking of A𝛼𝛼 chains over 𝛾𝛾 chains and 𝛾𝛾 dimers were not observed. Cross-linking at
the cell surface, in which the Aα chain reacts internally with a neighboring 𝛾𝛾 chain before it binds to the
cell, could lead to circulating monomeric fibrinogen containing intramolecular A𝛼𝛼 · 𝛾𝛾 complexes.
Alternatively, these complexes could form in the circulation when factor XIII becomes activated or
whenever a transglutaminase is released from a cell such as an erythrocyte (even through normal
senescent erythrocyte processing). Pathological conditions causing hemolysis and/or cell damage could
also result in increased levels of A𝛼𝛼 · 𝛾𝛾 heterodimers in circulating fibrinogen.
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